Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2025-08-28 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
第四届董事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 10th meeting of the 4th Board of Directors of Jiangsu Senxuan Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, and the voting results on various proposals such as approval of the 2025 semi-annual report, appointment of the accounting firm for 2025, amendments to the company charter, and internal management system revisions. The document references other filings where the actual reports and documents are disclosed (e.g., the 2025 semi-annual report, special reports, and announcements on the Beijing Stock Exchange information disclosure platform). The document itself does not contain the full financial report or detailed financial data but is a formal board meeting resolution announcement. This type of document fits the category of Board/Management Information (MANG), as it announces board meeting decisions and management-related resolutions.
2025-08-28 Chinese
独立董事工作细则
Governance Information Classification · 95% confidence The document is titled as the "Independent Director Work Rules" of Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the internal governance rules, qualifications, rights, duties, and procedures related to independent directors. It references relevant laws, regulations, and stock exchange rules, and includes procedural and governance content. There is no financial data, earnings information, or audit results. It is a governance-related document focusing on board structure and director responsibilities. It is not a report of financial results, audit, or a meeting announcement. Therefore, it fits best under Governance Information (CGR). The document length (13,459 characters) and detailed content confirm it is the full governance document, not just an announcement.
2025-08-28 Chinese
2025年1-6月募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the use, management, and status of funds raised through a public stock issuance by 江苏森萱医药股份有限公司. It includes specifics on the amount raised, usage of funds, management policies, approvals by the board and shareholders, and compliance with regulatory requirements. The document references the period January to June 2025 and contains financial figures and detailed explanations of fund allocation and usage. It is not a brief announcement or a certification letter but a substantive report on fundraising activities and fund management. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes.
2025-08-28 Chinese
承诺管理制度
Governance Information Classification · 95% confidence The document is a formal announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding the adoption and revision of the company's Commitment Management System. It details the internal management system, legal compliance, responsibilities of the company and related parties, and procedures for making and fulfilling commitments. The document includes voting results from a board meeting and states that the proposal will be submitted to the shareholders' meeting for approval. The content is about corporate governance and internal management policies rather than financial results, audit opinions, or regulatory filings. It is not a report itself but an announcement of a governance-related policy update. Therefore, the document fits best under Governance Information (CGR). The document length is 3175 characters, which is relatively short but contains substantive governance content, not just an announcement of a report publication or a regulatory filing. Hence, the classification is CGR with high confidence.
2025-08-28 Chinese
董事会审计委员会年报工作规程
Audit Report / Information Classification · 95% confidence The document is titled as the 'Board of Directors Audit Committee Annual Report Work Procedures' of Jiangsu Senxuan Pharmaceutical Co., Ltd. It details the internal procedures and responsibilities of the audit committee related to the preparation, review, and disclosure of the company's annual report and internal controls. The content focuses on governance, audit committee duties, communication with auditors, and internal control evaluations rather than presenting actual financial data or audit results. The document is relatively short (3015 characters) and reads as a procedural or governance document rather than a full audit report or annual report. It does not contain financial statements or audit opinions but outlines the process and responsibilities for the annual report audit work. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports, applied accounting principles, and internal control procedures, excluding full annual reports. It is not a regulatory filing or announcement, nor is it a management report or governance information report. Hence, the classification is AR with high confidence. FY 2025
2025-08-28 Chinese
独立董事津贴制度
Governance Information Classification · 95% confidence The document is an announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding the independent director remuneration system. It details the principles, standards, and conditions for paying allowances to independent directors, including legal references and company regulations. The document includes the board meeting date and voting results on the proposal, and states that the system will be submitted to the shareholders' meeting for approval. There are no financial statements or quarterly/yearly results, nor is this a report or presentation. It is a governance-related announcement about board policies and director compensation rules. Therefore, it fits best under Governance Information (CGR). The document length is short and focused on internal governance rules rather than financial or regulatory filings.
2025-08-28 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.